Tag Archives: Pieris Pharmaceuticals

Analysts Offer Insights on Healthcare Companies: Pieris Pharmaceuticals (NASDAQ: PIRS) and FibroGen (NASDAQ: FGEN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pieris Pharmaceuticals (PIRS – Research Report) and FibroGen (FGEN – Research Report). Pieris Pharmaceuticals (PIRS) William Blair analyst Matt Phipps maintained a Buy

William Blair Reaffirms Their Outperform Rating on Pieris Pharmaceuticals (PIRS)

In a report issued on July 21, Matt Phipps from William Blair reiterated an Outperform rating on Pieris Pharmaceuticals (NASDAQ: PIRS). The company’s shares closed last Friday at $2.70. The word on The Street in general, suggests a Moderate Buy

Analysts Are Bullish on Top Healthcare Stocks: Pieris Pharmaceuticals (PIRS), Roche Holding AG (RHHVF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pieris Pharmaceuticals (PIRS – Research Report) and Roche Holding AG (RHHVF – Research Report) with bullish sentiments. Pieris Pharmaceuticals (PIRS) H.C. Wainwright

Pieris Pharmaceuticals (PIRS) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Pieris Pharmaceuticals (PIRS – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $2.94, close to its 52-week low of $2.44. According

Pieris Pharmaceuticals (PIRS) Received its Third Buy in a Row

After Cowen & Co. and William Blair gave Pieris Pharmaceuticals (NASDAQ: PIRS) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Joseph Pantginis maintained a Buy rating on Pieris Pharmaceuticals today and set

Analysts Offer Insights on Healthcare Companies: Pieris Pharmaceuticals (NASDAQ: PIRS) and Nektar Therapeutics (NASDAQ: NKTR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pieris Pharmaceuticals (PIRS – Research Report) and Nektar Therapeutics (NKTR – Research Report) with bullish sentiments. Pieris Pharmaceuticals (PIRS) William Blair analyst